Pharming Gains FDA Priority Review for Lower-Dose Joenja
LEIDEN, Netherlands — September 25, 2026 Pharming Group N.V. announced that the U.S. Food and Drug Administration (FDA) has...
sNDA
Advertisement
Insmed Wins FDA Priority Review for ARIKAYCE sNDA
Bridgewater, New Jersey, U.S., September 21, 2026 Insmed has announced that the U.S. Food and Drug Administration (FDA) has...
DarioHealth Expands AI Care to 1.5 Million Lives
New York, New York, September 17, 2026 DarioHealth Corp. has announced a new contract with one of New Jersey’s...
Nuvation Bio IBTROZI Label Updated With Long-Term Data
New York, New York, September 17, 2026 Nuvation Bio Inc. has announced that the U.S. Food and Drug Administration...
Organon’s MIUDELLA FDA Review Advances Hormone-Free IUD
Jersey City, New Jersey, September 15, 2026 Organon has announced that the U.S. Food and Drug Administration (FDA) has...
Advertisements
Pharming Gains FDA Approval for Pediatric Joenja in APDS
LEIDEN, Netherlands — September 11, 2026 Pharming Group N.V. announced that the U.S. Food and Drug Administration (FDA) has...
Kazia Doses First Patient in Pediatric AT/RT Study
Sydney, Australia, September 10, 2026 Kazia Therapeutics Limited has announced that the first patient has been dosed in the...
BioMarin Reports Positive Phase 3 VOXZOGO Data
San Rafael, California, September 9, 2026 BioMarin Pharmaceutical Inc. has announced the publication of positive Phase 3 CANOPY-HCH-3 results...
United Therapeutics FDA Accepts Tyvaso sNDA for IPF
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., September 2, 2026 United Therapeutics Corporation announced that the U.S. Food...
Arrowhead Reports Phase 3 Plozasiran Data Reducing Pancreatitis
Pasadena, Calif. – August 30, 2026 Arrowhead Pharmaceuticals presented detailed Phase 3 SHASTA-3 and SHASTA-4 data showing that plozasiran...
Advertisement
